Related Experiment Video
Updated: Feb 5, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
Naoise C Synnott1, Stephen F Madden2, Vladimir J N Bykov3
1UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
Abstract:
TP53 is the most frequently mutated gene in human cancer and thus an attractive target for novel cancer therapy. Several compounds that can reactive mutant p53 protein have been identified. APR-246 is currently being tested in a phase II clinical trial in high-grade serous ovarian cancer. We have used RNA-seq analysis to study the effects of APR-246 on gene expression in human breast cancer cell lines. Although the effect of APR-246 on gene expression was largely cell line dependent, six genes were upregulated across all three cell lines studied, i.e., TRIM16, SLC7A11, TXNRD1, SRXN1, LOC344887, and SLC7A11-AS1. We did not detect upregulation of canonical p53 target genes such as CDKN1A (p21), 14-3-3σ, BBC3 (PUMA), and PMAIP1 (NOXA) by RNA-seq, but these genes were induced according to analysis by qPCR. Gene ontology analysis showed that APR-246 induced changes in pathways such as response to oxidative stress, gene expression, cell proliferation, response to nitrosative stress, and the glutathione biosynthesis process. Our results are consistent with the dual action of APR-246, i.e., reactivation of mutant p53 and modulation of redox activity. SLC7A11, TRIM16, TXNRD1, and SRXN1 are potential new pharmacodynamic biomarkers for assessing the response to APR-246 in both preclinical and clinical studies.
Insights
APR-246 reactivates mutant p53 and affects gene expression in breast cancer cells. Six genes, including SLC7A11 and TRIM16, were upregulated, suggesting potential biomarkers for treatment response.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- The TP53 gene is frequently mutated in human cancers, making mutant p53 a key therapeutic target.
- APR-246 is an investigational drug designed to reactivate mutant p53 and is in clinical trials for ovarian cancer.
- Understanding APR-246's molecular effects on gene expression is crucial for optimizing its therapeutic application.
Purpose of the Study:
- To investigate the effects of APR-246 on gene expression in human breast cancer cell lines using RNA-sequencing.
- To identify genes and pathways modulated by APR-246 treatment.
- To explore potential pharmacodynamic biomarkers for APR-246 response.
Main Methods:
- RNA-sequencing (RNA-seq) was employed to analyze gene expression changes in three human breast cancer cell lines treated with APR-246.
- Quantitative Polymerase Chain Reaction (qPCR) was used to validate the expression of specific p53 target genes.
- Gene Ontology (GO) analysis was performed to identify affected biological pathways.
Main Results:
- APR-246 treatment led to cell line-dependent gene expression changes.
- Six genes (TRIM16, SLC7A11, TXNRD1, SRXN1, LOC344887, and SLC7A11-AS1) were consistently upregulated across all tested cell lines.
- While canonical p53 target genes were not significantly upregulated by RNA-seq, qPCR confirmed their induction. GO analysis revealed impacts on oxidative stress, gene expression, cell proliferation, nitrosative stress, and glutathione biosynthesis.
Conclusions:
- APR-246 exhibits a dual mechanism of action, involving mutant p53 reactivation and redox modulation.
- Specific genes such as SLC7A11, TRIM16, TXNRD1, and SRXN1 show promise as pharmacodynamic biomarkers for APR-246.
- These findings support the continued investigation of APR-246 in preclinical and clinical cancer studies.
More Related Videos
04:56Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mechanisms of Retrovirus-induced Cancers
Induced Pluripotent Stem Cells
Organic Compounds
Cell Specific Gene Expression